{"log_id": 2835696051852771634, "direction": 0, "words_result_num": 28, "words_result": [{"probability": {"variance": 0, "average": 0.719986, "min": 0.719986}, "location": {"width": 22, "top": 59, "height": 27, "left": 1105}, "words": "邊"}, {"probability": {"variance": 0.015459, "average": 0.936377, "min": 0.376559}, "location": {"width": 866, "top": 95, "height": 90, "left": 141}, "words": "ST升高>5×正常值上限(ULN)或总胆红素升高>3xULN,须停药且勿再使用本品(见药代动"}, {"probability": {"variance": 0.000507, "average": 0.981023, "min": 0.949326}, "location": {"width": 60, "top": 199, "height": 31, "left": 140}, "words": "力学)"}, {"probability": {"variance": 0.025078, "average": 0.932645, "min": 0.357547}, "location": {"width": 834, "top": 193, "height": 83, "left": 183}, "words": "严重肝功能损( child-pugh C级)患者不得使用本品。另一项试验在8例基线严重肝功能损"}, {"probability": {"variance": 0.010786, "average": 0.963856, "min": 0.486713}, "location": {"width": 873, "top": 243, "height": 87, "left": 144}, "words": "害( child-pugh C级)受试者和8例肝功能正常的健康对照受试者中分析了阿比特龙的药物代谢"}, {"probability": {"variance": 0.002603, "average": 0.974019, "min": 0.759019}, "location": {"width": 882, "top": 287, "height": 89, "left": 147}, "words": "动力学。与肝功能正常的受试者相比。基线严重肝功能损害受试者的阿比特龙全身暴露量(AUC"}, {"probability": {"variance": 0.001603, "average": 0.988263, "min": 0.818846}, "location": {"width": 411, "top": 367, "height": 54, "left": 149}, "words": "增加7倍,游离药物部分的暴露量增加2倍"}, {"probability": {"variance": 0.019149, "average": 0.909264, "min": 0.539941}, "location": {"width": 832, "top": 462, "height": 81, "left": 199}, "words": "对本品治疗期间发生肝毒性的患者(ALT和/或AST>5xOLN或总胆红素>3XLN2,应暂时中"}, {"probability": {"variance": 8.8e-05, "average": 0.992273, "min": 0.97902}, "location": {"width": 68, "top": 468, "height": 27, "left": 155}, "words": "肝毒性"}, {"probability": {"variance": 0.009247, "average": 0.9581, "min": 0.541809}, "location": {"width": 873, "top": 509, "height": 83, "left": 161}, "words": "断本品治疗并调整剂量(见注意事项)。在肝功能水平恢复到基线水平或AST和ALTS2.5×ULN且"}, {"probability": {"variance": 0.010204, "average": 0.956998, "min": 0.602355}, "location": {"width": 876, "top": 556, "height": 83, "left": 164}, "words": "总胆红素≤1.5x0LN后,可降低剂量至750mg每日1次再次治疗。对恢复治疗患者,至少每2"}, {"probability": {"variance": 0.000213, "average": 0.991931, "min": 0.929815}, "location": {"width": 577, "top": 620, "height": 65, "left": 165}, "words": "周监测1次血清转氨酶和胆红素水平,3个月后每月监测1次"}, {"probability": {"variance": 0.001442, "average": 0.984213, "min": 0.783568}, "location": {"width": 826, "top": 650, "height": 79, "left": 210}, "words": "如果750mg每日1次给药时再次发生肝毒性,可在肝功能检查值恢复到基线水平或AST"}, {"probability": {"variance": 0.019492, "average": 0.925589, "min": 0.506632}, "location": {"width": 759, "top": 701, "height": 76, "left": 173}, "words": "和AT25xULN并且总胆红素≤1.5XUN后,降低剂量至500mg每日1次再次治疗"}, {"probability": {"variance": 0.009848, "average": 0.948035, "min": 0.605239}, "location": {"width": 831, "top": 740, "height": 80, "left": 217}, "words": "如果500mg每日1次给药时再次发生肝毒性,须停药。尚不清楚在AST或AT20XULN和"}, {"probability": {"variance": 0.019593, "average": 0.948491, "min": 0.464838}, "location": {"width": 519, "top": 807, "height": 61, "left": 173}, "words": "或胆红素≥10×ULN患者中再次使用本品治疗的安全性"}, {"probability": {"variance": 0.000121, "average": 0.99426, "min": 0.959599}, "location": {"width": 286, "top": 913, "height": 46, "left": 183}, "words": "肾功能损害情况下的剂量调整"}, {"probability": {"variance": 0.003937, "average": 0.974932, "min": 0.655001}, "location": {"width": 829, "top": 926, "height": 78, "left": 230}, "words": "对肾功能损害患者,无需进行剂量调整(见药代动力学。但在重度肾功能损害的前列腺癌"}, {"probability": {"variance": 6.3e-05, "average": 0.994435, "min": 0.965794}, "location": {"width": 433, "top": 999, "height": 49, "left": 189}, "words": "患者中尚无临床经验。此类者建议谨慎使用"}, {"probability": {"variance": 0.00123, "average": 0.977391, "min": 0.859675}, "location": {"width": 385, "top": 1047, "height": 49, "left": 190}, "words": "合并使用强CYP3A4诱导剂时的剂量调整"}, {"probability": {"variance": 0.015474, "average": 0.945054, "min": 0.428407}, "location": {"width": 829, "top": 1070, "height": 70, "left": 237}, "words": "本品治疗期间避免合并使用强CYP3A4锈导剂(如苯妥英钠卡马西平、利福平、利福布"}, {"probability": {"variance": 0.020334, "average": 0.939593, "min": 0.407917}, "location": {"width": 921, "top": 1105, "height": 84, "left": 195}, "words": "汀、利福喷丁、苯巴比妥虽然尚无关于接受强CYP3A4诱导剂治疗期间本品剂置调整的临床"}, {"probability": {"variance": 0.031431, "average": 0.907079, "min": 0.354285}, "location": {"width": 988, "top": 1133, "height": 102, "left": 199}, "words": "数据,但鉴于潜在的相互作用,如果必须合并使用强CP3A导剂,需在合并用药期间增加"}, {"probability": {"variance": 0.00911, "average": 0.962271, "min": 0.545567}, "location": {"width": 928, "top": 1210, "height": 70, "left": 202}, "words": "本品的给药频率至每日2次(例如,从1000mg每日1次增至1000mg每日2次)在停止合"}, {"probability": {"variance": 0.019839, "average": 0.954374, "min": 0.389523}, "location": {"width": 944, "top": 1249, "height": 77, "left": 203}, "words": "并使用强CYP3A4诱导剂后,应将本品调整至原给药剂量和频率见药物相互作用和药代动"}, {"probability": {"variance": 0.000666, "average": 0.972547, "min": 0.946739}, "location": {"width": 36, "top": 1340, "height": 24, "left": 210}, "words": "学)"}, {"probability": {"variance": 0.00025, "average": 0.989387, "min": 0.956659}, "location": {"width": 115, "top": 1412, "height": 28, "left": 219}, "words": "【不良反应】"}, {"probability": {"variance": 0.000132, "average": 0.993182, "min": 0.965512}, "location": {"width": 157, "top": 1460, "height": 35, "left": 212}, "words": "安全性特征概要"}], "language": 3}